公开(公告)号：EP2050335A1

公开(公告)日：2009-04-22

申请号：EP08020669.1

申请日：2007-02-09

申请人： Genentech, Inc. ,  Lexicon Pharmaceuticals, Inc.

发明人： Bollinger, Kristi Rae ,  Horner, Allison Anne Byers ,  Combs, Katherin E. ,  Culbertson, Ling Ling ,  Cunningham, Jaime-jo ,  Desauvage, Frederic ,  Edwards, Joel ,  Girgis, Rosemary ,  Green, Leslie ,  McLain, Dina Rebecca ,  Minze, Laurie Jeanette ,  Montgomery, Charles A. ,  Payne, Bobby Joe ,  Phillips, Heidi ,  Shi, Zheng-Zheng ,  Sparks, Mary Jean ,  Stala, Joy ,  Tang, Tracy Tsu-Ling ,  Townsend, Teresa Gail ,  Vogel, Peter ,  Willis-Sevaux, Tracy Ellen

IPC分类号： A01K67/027 ,  A61K39/395 ,  C07K14/47 ,  C07K14/515 ,  C07K16/18 ,  G01N33/50

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C12N15/8509

摘要： The present invention relates to transgenic animals, as wells as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO188, PRO235, PRO266, PRO337, PRO361, PRO539, PRO698, PRO717, PRO846, PRO874, PRO98346, PRO1082, PRO1097, PRO1192, PRO1268, PRO1278, PRO1303, PRO1308, PRO1338, PRO1378, PRO1415, PRO1867, PRO1890, PRO3438, PRO19835, PRO36915, PRO36029, PRO4999, PRO5778, PRO5997, PRO6079, PRO6090, PRO7178, PR021184, PRO7434, PRO9822, PRO8933, PRO9836, PRO9854, PRO9863, PRO10284, PRO37510, PRO35444, PRO20473, PRO21054 or PRO35246 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration, or correction of diseases or dysfunctions associated with gene disruptions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorder; or developmental abnormalities.

摘要翻译： 本发明涉及转基因动物，如作为与基因功能表征有关的组合物和方法的孔。 具体地说，本发明提供转基因小鼠，其包括PRO188，PRO235，PRO266，PRO337，PRO361，PRO539，PRO698，PRO717，PRO846，PRO874，PRO98346，PRO1082，PRO1097，PRO1192，PRO1268，PRO1278，PRO1303，PRO1308，PRO1338，PRO1378中的中断 ，PRO1415，PRO1867，PRO1890，PRO3438，PRO19835，PRO36915，PRO36029，PRO4999，PRO5778，PRO5997，PRO6079，PRO6090，PRO7178，PR021184，PRO7434，PRO9822，PRO8933，PRO9836，PRO9854，PRO9863，PRO10284，PRO37510，PRO35444，PRO20473，PRO21054 或PRO35246基因。 这样的体内研究和表征可以提供有用的鉴定和发现治疗和/或治疗，其用于预防，改善或矫正与基因破坏相关的疾病或功能障碍相关的基因紊乱，例如神经障碍; 心血管，内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂质代谢紊乱; 或发育异常。

公开(公告)号：EP2002714A1

公开(公告)日：2008-12-17

申请号：EP08012287.2

申请日：2006-11-16

申请人： Genentech, Inc. ,  Lexicon Pharmaceuticals, Inc.

发明人： Byers-Horner, Allison Anne ,  Combs, Katherin ,  Desauvage, Frederic ,  Fan, Liangfen ,  Filvaroff, Ellen ,  Irving, Bryan ,  Junutula, Jagath Reddy ,  Massey, Erin Marie ,  McLain, Dina Rebecca ,  Minze, Laurie Jeannette ,  Montgomery, Charles A. ,  Payne, Bobby Joe ,  Phillips, Heidi ,  Rangel, Carolina ,  Shi, Zheng-zheng ,  Sparks, Mary Jean ,  Stala, Joy ,  Townsend, Teresa Gail ,  Vogel, Peter ,  Willis-Sevaux, Tracy Ellen

IPC分类号： A01K67/027 ,  A61K49/00

CPC分类号： C12Q1/6883 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K49/0008 ,  C12N15/8509 ,  C12Q2600/158

摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069 PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

摘要翻译： 本发明涉及转基因动物，以及与基因功能表征相关的组合物和方法。 具体地说，本发明提供转基因小鼠，其包括PRO218，PRO228，PRO271，PRO273，PRO295，PRO302，PRO305，PRO326，PRO386，PRO655，PRO162，PRO788，PRO792，PRO940，PRO941，PRO1004，PRO1012，PRO1016，PRO474，PRO5238 ，PRO1069 PRO1111，PRO1113，PRO1130，PRO1195，PRO1271，PRO1865，PRO1879，PRO3446，PRO3543，PRO4329，PRO4352，PRO5733，PRO9859，PRO9864，PRO9904，PRO9907，PRO10013，PRO90948，PRO28694，PRO16089，PRO19563，PRO19675，PRO20084，PRO21434， PRO50332，PRO38465或PRO346基因。 这样的体内研究和表征可以提供有用的识别和发现用于预防，改善或矫正与基因中断（例如神经障碍）相关的疾病或功能障碍的治疗和/或治疗; 心血管，内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂质代谢紊乱; 或发育异常。